Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) is scheduled to announce Q3 earnings results on Thursday, August 8th, after market close. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $37.
14M (+134.6% Y/Y). Over the last 1 year, ARWR has beaten EPS estimates 25% of the time and has beaten revenue estimates 50% of the time.
Over the last 3 months, EPS estimates have seen 6 upward revisions and 2 downward. Revenue estimates have seen 6 upward revisions and 1 downward. More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Driving To Commercialization Arrowhead Pharmaceuticals: Hoping Something Sticks Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point Goldman starts Arrowhead at neutral, cites RNAi portfolio validation Arrowhead says phase 3 trial of rare metabolic disease asset plozasiran meets goals.